Which of the following is an advantage of Montelukast over other LTRAs?

Montelukast is a leukotriene receptor antagonist (LTRA) that offers several advantages over other medications in its class. One significant benefit is that it can be safely administered to children starting at six months of age. This early use is particularly important for managing conditions like asthma and allergic rhinitis in young patients, allowing for timely intervention and symptom control.

Other options do not present advantages. A higher incidence of side effects (such as option A) does not qualify as an advantage, nor do more drug interactions (option B), which would complicate therapy rather than improve it. Requiring a prescription from a specialist (option D) limits access to the medication, making it less advantageous compared to other options that might not have such restrictions. Hence, the ability to use Montelukast in younger children is a clear clinical advantage, supporting early treatment in pediatric care.